To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Jason Harris
Keytruda (pembrolizumab) was granted a priority review by the Food and Drug Administration (FDA) for the treatment of patients with advanced cervical cancer with disease progression or after chemotherapy.
Brielle Urciuoli
The International Myeloma Foundation declared March to be Myeloma Action Month to help raise awareness about the disease.
Kristie L. Kahl
Next-generation sequencing could help identify MSI-H status in patients, which could have important implications for treatment plans.
Brielle Urciuoli
New targeted therapies and immunotherapy treatments have rapidly improved the outcomes of patients with cancer. But not everyone is so lucky to have access to these agents.
Kristie L. Kahl
Fear of recurrence is one of the most prominent concerns for patients with cancer, but oncology team interventions may play an important role in helping.
Kristie L. Kahl
Cognitive dysfunction among geriatric patients with blood cancers – such as multiple myeloma, leukemia and lymphoma – is not only prevalent, but may also impact long-term survival.
Kristie L. Kahl
TransCelerate BioPharma, a non-profit organization, launched a campaign to address the high demands and low enrollment of clinical trials for cancer treatment.
Katie Kosko
“There have been significant developments in our underpinnings for the development of pancreas cancer on both a molecular and genetic basis," said Eileen M. O'Reilly, M.D.
Kristie L. Kahl
The agency determined the Personal Genome Service Genetic Health Risk (GHR) Report is accurate and can provide reproducible results.
The Food and Drug Administration (FDA) has approved a supplemental biologics license application adding a four-week dosing schedule for Opdivo (nivolumab) across several of the PD-1 inhibitor’s indications.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable